Non-Invasive Cancer Diagnostics Market

Non-invasive Cancer Diagnostics Market (Test Type: Urine Test, Imaging Test, and Spectroscopy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Non-invasive Cancer Diagnostics Market Outlook 2031

  • The global non-invasive cancer diagnostics market was valued at US$ 104.8 Bn in 2021
  • The global market is projected to grow at a CAGR of 7.0% from 2022 to 2031
  • The global non-invasive cancer diagnostics market is anticipated to reach more than US$ 207 Bn by 2031

Analysts’ Viewpoint on Non-invasive Cancer Diagnostics Market Scenario

Cancer awareness and early detection have increased over the last few decades, resulting in a decrease in mortality rates. Early diagnosis requires ensuring rapid patient presentation, diagnosis, and treatment. Advancements in sensors, contrast agents, molecular methods, and Artificial Intelligence (AI) that assist in detecting cancer-specific signals in real time is expected to drive the global non-invasive cancer diagnostics market during the forecast period. Risk-based detection and prevention needs to be cost-effective and widely accessible in order to reduce the burden of cancer on the society. Maximizing detection accuracy with a cost-effective approach facilitated by non-invasive cancer diagnostic techniques is likely to propel the global market in the next few years. Companies in the market are investing significantly in the research & development of improved non-invasive cancer diagnostics.

Non Invasive Cancer Diagnostics Market

Non-invasive Cancer Diagnostics Market Introduction

Cancer is a disease, in which some of the body's cells grow uncontrollably and spread to other parts. It is a group of more than 100 different diseases, which develop almost anywhere in the body. Diagnostic testing of cancer involves tests and procedures to confirm the presence of the disease, and identification of the correct tumor type, location, extent, and stage. Cancer diagnosis is performed with various methods or techniques such as physical exam, laboratory tests, imaging tests, and biopsy. Oncologists use one or more approaches to diagnose cancer. These techniques are categorized into invasive or minimally invasive and non-invasive. Invasive cancer diagnosis (painstaking cancer diagnosis) or minimally invasive cancer diagnosis techniques include laboratory test (blood test) and biopsy, while non-invasive cancer diagnosis (unintrusive cancer diagnosis) techniques comprise imaging tests, physical exam, spectroscopy, and laboratory test (urine test).

Increase in geriatric population, surge in incidence of cancer, rise in technological advancements in imaging equipment, and shift in preference toward non-invasive cancer diagnosis techniques are the major factors propelling the global market. According to the World Health Organization (WHO), the global population aged 60 years or above stood at 1 billion in 2020 and is anticipated to reach 1.4 billion by 2030 and 2.1 billion by 2050. Thus, the population of people aged 60 years and older will double by 2050 compared to that in 2020. Furthermore, the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million by 2050. This geriatric population is more prone to chronic diseases such as cancer. This is projected to boost the demand for cancer diagnosis. In turn, this is anticipated to augment the global non-invasive cancer diagnostics market size from 2022 to 2031. According to statistics published by the Global Cancer Observatory, the number of new cancer cases across the world stood at 19,292,789 in 2020.

Request a sample to get extensive insights into the ­­­Non-invasive Cancer Diagnostics Market

COVID-19 Impact on Global Non-invasive Cancer Diagnostics Market

COVID-19 had a negative effect on the non-invasive cancer diagnostics market in 2020. The unprecedented outbreak of the COVID-19 pandemic largely affected countries in North America and Europe such as the U.S., Italy, Spain, the U.K., France, and Germany. Implementation of lockdowns due to COVID-19 outbreak delayed the diagnosis of cancer. It also affected the logistics and supply of cancer diagnosis equipment or products. Nationwide lockdowns, government regulations, and increase in infection rate across countries created a widespread financial impact on cancer hospitals and outpatient centers. Several hospitals and clinics witnessed a drop in number of patient visits amid COVID-19, ultimately reducing client contact. Furthermore, several cancer diagnostic procedures and non-invasive cancer treatments were delayed due to the pandemic. Limited availability of healthcare staff was another factor that restrained the cancer diagnostics market.

Easy to Perform and Lower Cost Features Propelling Imaging Test Segment

In terms of test type, the imaging test segment held the largest global non-invasive cancer diagnostics market share in 2021. The trend is expected to continue during the forecast period due to the increase in patient preference for imaging tests. Ultrasound, Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), mammography, Positron Emission Tomography (PET), X-ray/mammography, and liquid biopsy are non-invasive diagnostic tests for cancer detection. These tests are simpler and less expensive than blood or plasma tests. Hence, increasing number of cancer patients are opting for painless imaging tests to diagnose and monitor cancer progression.

The urine test segment is likely to dominate the global non-invasive cancer diagnostics market during the forecast period owing to the rise in adoption of the urinalysis test to check for traces of blood, bacteria, or abnormal cells in the urine in cancer or bladder cancer diagnosis cases.

Request a custom report on ­­­Non-invasive Cancer Diagnostics Market

Surge in Incidence of Breast Cancer Across Globe

Based on cancer type, the breast cancer segment held substantial share of the global market in 2021. This can be ascribed to the surge in incidence of breast cancer across the globe and increase in population of women aged 50 to 74. Rise in initiatives by various organizations for early screening and diagnosis of breast cancer is projected to augment the segment in the next few years. According to the Global Cancer Observatory, 2,261,419 breast cancer cases were reported across the world in 2020.

Lung cancer is projected to be a lucrative segment of the global market during the forecast period, as it is the leading cancer in the U.S. and across the globe. According to the Centers for Disease Control and Prevention (CDC), cigarette smoking is linked to about 80% to 90% of lung cancer deaths in the U.S. Rise in usage of chest X-ray, CT, MRI, PET, and bone scans for lung cancer diagnosis is likely to propel the lung cancer segment from 2022 to 2031.

Rise in Non-invasive Cancer Diagnostic Procedures Driving Hospitals & Clinics Segment

In terms of end-user, the hospitals & clinics segment held the largest share of the global market in 2021. This can be ascribed to the increase in number of hospitals and rise in non-invasive cancer diagnostic procedures in this setting. According to the American Hospital Association (AHA), the number of hospitals in the U.S. rose from 5,564 in 2017 to 6,093 in 2022. Increase in number of hospitals in the region has led to a surge in number of cancer diagnosis tests performed.

Regional Analysis of Non-Invasive Cancer Diagnostics Market

According to the global non-invasive cancer diagnostics market analysis, North America accounted for significant share of the market in 2021. This can be ascribed to changing demographics, evolving lifestyle, increase in incidence of cancer, and presence of well-established point-of-care diagnostic centers in the U.S. and Canada. For instance, the number of new cancer cases in North America stood at 2,556,862 in 2020.

The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in geriatric population, surge in incidence of cancer, and rise in awareness about non-invasive equipment for cancer diagnosis are expected to augment the market in the region during the forecast period. Governments of Japan, China, and India fund and support universities and research institutes in order to develop new technologies for cancer diagnosis. This is driving the market for non-invasive cancer diagnostics in the region.

Analysis of Key Players in Global Non-invasive Cancer Diagnostics Market

The non-invasive cancer diagnostics market report concludes with the company profiles section that includes key information about the major players in the global non-invasive cancer diagnostics market. Market participants are focusing on strategies such as new product or solution offerings, mergers, and partnerships & collaborations to compete in the global market. The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beverly Hills Cancer Center, SimonMed Imaging, RadNet Management, Inc., RAYUS Radiology (Diagnostic Services Holdings, Inc.), Unilabs AB, Sonic Healthcare Limited, and Dr Lal PathLabs Ltd. are the prominent players operating in the global market.

Key Developments in Global Non-Invasive Cancer Diagnostics Market

  • In October 2022, RadNet, Inc.’s joint venture, New Jersey Imaging Network (NJIN), acquired the outpatient radiology assets of Montclair Radiology, the owner of six imaging centers in northern New Jersey. Through this move, RadNet aims to strengthen its position as a provider of outpatient imaging in northern and central New Jersey. It aims to offer high-quality, lower cost, and convenient services as an alternative to more expensive hospital-based imaging.
  • In July 2022, Unilabs Sweden partnered with Subtle Medical, a healthcare technology company using artificial intelligence for faster and higher quality MRI, to improve the quality and efficiency of their MRI imaging. Subtle Medical's SubtleMR would assist radiologists in performing high-quality imaging more efficiently. SubtleMR is an AI-powered software that improves image quality from upward of 60% faster scan times. The software has been clinically validated in multiple peer-reviewed journals, showing clinical quality and integrity across diverse sites, scanners, and patients.

Each of these players has been profiled in the non-invasive cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Non-invasive Cancer Diagnostics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 104.8 Bn

Market Forecast Value in 2031

More than US$ 207 Bn

Compound Annual Growth Rate (CAGR)

7.0%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Test Type
    • Urine Test
    • Imaging Test
      • Computerized Tomography
      • Magnetic Resonance Imaging
      • Nuclear Medicine Scans
      • X-ray/Mammography
      • Ultrasound
    • Spectroscopy
  • Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Blood Cancer
    • Ovarian Cancer
    • Colorectal Cancer
    • Others
  • End-user
    • Hospitals & Clinics
    • Ambulatory Care
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • The University of Texas MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Dana-Farber Cancer Institute
  • Beverly Hills Cancer Center
  • SimonMed Imaging
  • RadNet Management, Inc.
  • RAYUS Radiology (Diagnostic Services Holdings, Inc.)
  • Unilabs AB
  • Sonic Healthcare Limited
  • Dr Lal PathLabs Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global non-invasive cancer diagnostics market in 2021?

The global non-invasive cancer diagnostics market was valued at US$ 104.8 Bn in 2021

How big will be the global non-invasive cancer diagnostics market by 2031?

The global non-invasive cancer diagnostics market is projected to reach more than US$ 207 Bn by 2031

What will be the CAGR of the global non-invasive cancer diagnostics market during the forecast period (2022–2031)?

The global non-invasive cancer diagnostics market is anticipated to grow at a CAGR of 7.0% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in geriatric population, rise in incidence of cancer, surge in technological advancements in imaging equipment, and shift in preference toward non-invasive cancer diagnosis techniques

What was the market share of the leading segment of the global non-invasive cancer diagnostics market?

The imaging test segment accounted for more than 59% share of the global non-invasive cancer diagnostics market in 2021

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global non-invasive cancer diagnostics market during the forecast period

Who are the prominent players in the global non-invasive cancer diagnostics market?

The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Beverly Hills Cancer Center, SimonMed Imaging, RadNet Management, Inc., RAYUS Radiology (Diagnostic Services Holdings, Inc.), Unilabs AB, Sonic Healthcare Limited, and Dr Lal PathLabs Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Non-invasive Cancer Diagnostics Market

    4. Market Overview

        4.1. Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. Global Non-invasive Cancer Diagnostics Market Value Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Test Type, 2017–2031

            6.3.1. Urine Test

            6.3.2. Imaging Test

                6.3.2.1. Computerized Tomography

                6.3.2.2. Magnetic Resonance Imaging

                6.3.2.3. Nuclear Medicine Scans

                6.3.2.4. X-ray/Mammography

                6.3.2.5. Ultrasound

            6.3.3. Spectroscopy

        6.4. Market Attractiveness Analysis, by Test Type

    7. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Cancer Type, 2017–2031

            7.3.1. Breast Cancer

            7.3.2. Lung Cancer

            7.3.3. Blood Cancer

            7.3.4. Ovarian Cancer

            7.3.5. Colorectal Cancer

            7.3.6. Others

        7.4. Market Attractiveness Analysis, by Cancer Type

    8. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals & Clinics

            8.3.2. Ambulatory Care

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Non-invasive Cancer Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Test Type, 2017–2031

            10.2.1. Urine Test

            10.2.2. Imaging Test

                10.2.2.1. Computerized Tomography

                10.2.2.2. Magnetic Resonance Imaging

                10.2.2.3. Nuclear Medicine Scans

                10.2.2.4. X-ray/Mammography

                10.2.2.5. Ultrasound

            10.2.3. Spectroscopy

        10.3. Market Value Forecast, by Cancer Type, 2017–2031

            10.3.1. Breast Cancer

            10.3.2. Lung Cancer

            10.3.3. Blood Cancer

            10.3.4. Ovarian Cancer

            10.3.5. Colorectal Cancer

            10.3.6. Others

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals & Clinics

            10.4.2. Ambulatory Care

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Test Type

            10.6.2. By Cancer Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Test Type, 2017–2031

            11.2.1. Urine Test

            11.2.2. Imaging Test

                11.2.2.1. Computerized Tomography

                11.2.2.2. Magnetic Resonance Imaging

                11.2.2.3. Nuclear Medicine Scans

                11.2.2.4. X-ray/Mammography

                11.2.2.5. Ultrasound

            11.2.3. Spectroscopy

        11.3. Market Value Forecast, by Cancer Type, 2017–2031

            11.3.1. Breast Cancer

            11.3.2. Lung Cancer

            11.3.3. Blood Cancer

            11.3.4. Ovarian Cancer

            11.3.5. Colorectal Cancer

            11.3.6. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals & Clinics

            11.4.2. Ambulatory Care

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Test Type

            11.6.2. By Cancer Type

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Test Type, 2017–2031

            12.2.1. Urine Test

            12.2.2. Imaging Test

                12.2.2.1. Computerized Tomography

                12.2.2.2. Magnetic Resonance Imaging

                12.2.2.3. Nuclear Medicine Scans

                12.2.2.4. X-ray/Mammography

                12.2.2.5. Ultrasound

            12.2.3. Spectroscopy

        12.3. Market Value Forecast, by Cancer Type, 2017–2031

            12.3.1. Breast Cancer

            12.3.2. Lung Cancer

            12.3.3. Blood Cancer

            12.3.4. Ovarian Cancer

            12.3.5. Colorectal Cancer

            12.3.6. Others

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals & Clinics

            12.4.2. Ambulatory Care

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Test Type

            12.6.2. By Cancer Type

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Test Type, 2017–2031

            13.2.1. Urine Test

            13.2.2. Imaging Test

                13.2.2.1. Computerized Tomography

                13.2.2.2. Magnetic Resonance Imaging

                13.2.2.3. Nuclear Medicine Scans

                13.2.2.4. X-ray/Mammography

                13.2.2.5. Ultrasound

            13.2.3. Spectroscopy

        13.3. Market Value Forecast, by Cancer Type, 2017–2031

            13.3.1. Breast Cancer

            13.3.2. Lung Cancer

            13.3.3. Blood Cancer

            13.3.4. Ovarian Cancer

            13.3.5. Colorectal Cancer

            13.3.6. Others

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals & Clinics

            13.4.2. Ambulatory Care

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Test Type

            13.6.2. By Cancer Type

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Test Type, 2017–2031

            14.2.1. Urine Test

            14.2.2. Imaging Test

                14.2.2.1. Computerized Tomography

                14.2.2.2. Magnetic Resonance Imaging

                14.2.2.3. Nuclear Medicine Scans

                14.2.2.4. X-ray/Mammography

                14.2.2.5. Ultrasound

            14.2.3. Spectroscopy

        14.3. Market Value Forecast, by Cancer Type, 2017–2031

            14.3.1. Breast Cancer

            14.3.2. Lung Cancer

            14.3.3. Blood Cancer

            14.3.4. Ovarian Cancer

            14.3.5. Colorectal Cancer

            14.3.6. Others

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals & Clinics

            14.4.2. Ambulatory Care

            14.4.3. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Test Type

            14.6.2. By Cancer Type

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Company Profiles

            15.2.1. The University of Texas MD Anderson Cancer Center

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Company Financials

                15.2.1.3. Growth Strategies

                15.2.1.4. SWOT Analysis

            15.2.2. Memorial Sloan Kettering Cancer Center

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Company Financials

                15.2.2.3. Growth Strategies

                15.2.2.4. SWOT Analysis

            15.2.3. Dana-Farber Cancer Institute

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Company Financials

                15.2.3.3. Growth Strategies

                15.2.3.4. SWOT Analysis

            15.2.4. Beverly Hills Cancer Center

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Company Financials

                15.2.4.3. Growth Strategies

                15.2.4.4. SWOT Analysis

            15.2.5. SimonMed Imaging

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Company Financials

                15.2.5.3. Growth Strategies

                15.2.5.4. SWOT Analysis

            15.2.6. RadNet Management, Inc.

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Company Financials

                15.2.6.3. Growth Strategies

                15.2.6.4. SWOT Analysis

            15.2.7. RAYUS Radiology (Diagnostic Services Holdings, Inc.)

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.7.2. Company Financials

                15.2.7.3. Growth Strategies

                15.2.7.4. SWOT Analysis

            15.2.8. Unilabs AB

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Company Financials

                15.2.8.3. Growth Strategies

                15.2.8.4. SWOT Analysis

            15.2.9. Sonic Healthcare Limited

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Company Financials

                15.2.9.3. Growth Strategies

                15.2.9.4. SWOT Analysis

            15.2.10. Dr Lal PathLabs Ltd.

                15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.10.2. Company Financials

                15.2.10.3. Growth Strategies

                15.2.10.4. SWOT Analysis

    List of Tables

    Table 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 02: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 03: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 06: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 07: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 08: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 10: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 11: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 14: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 15: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 16: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 18: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 19: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 20: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 21: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

    Table 22: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

    Table 23: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 24: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 03: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 04: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031

    Figure 05: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 06: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 07: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 08: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region, 2021 and 2031

    Figure 09: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 10: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 12: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 13: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

    Figure 14: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 15: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 16: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 17: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country, 2021 and 2031

    Figure 18: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 19: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 20: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 21: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 22: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type. 2021 and 2031

    Figure 23: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 24: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 25: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 26: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 27: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 28: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 29: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 30: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 31: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031

    Figure 32: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 33: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 34: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 35: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 36: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 37: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 38: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 39: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 40: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

    Figure 41: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 42: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 43: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 44: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 45: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 46: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 47: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

    Figure 48: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

    Figure 49: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

    Figure 50: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

    Figure 51: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

    Figure 52: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 53: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 54: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 55: Global Non-invasive Cancer Diagnostics Market Share Analysis/Ranking, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved